Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Scribe Therapeutics, Inc. (SCTX) had 13 insider filings in the last 90 days, with the most recent on 2026-07-29. The full record for SCTX runs to 13 Form 4 filings, the earliest from 2026-07-28. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying SCTX stock?
9 insider purchases of SCTX were filed in the last 90 days, totaling $71.34M.
How many insiders are selling SCTX stock?
No insider sales of SCTX were filed in the last 90 days.
Where can I see SCTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks SCTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow SCTX insider buys?
Create a free InsiderAlpha account and press Watch on this page to add SCTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
